Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.62 |
| ▸ | CES1 | P23141 | 4/20 | 0.62 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.59 |
| ▸ | PPARG | P37231 | 7/20 | 0.59 |
| ▸ | PPARD | Q03181 | 7/20 | 0.59 |
| ▸ | PPARA | Q07869 | 7/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.59 |
| ▸ | TSHR | P16473 | 5/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | TLR2 | O60603 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | FABP4 | P15090 | 2/20 | 0.59 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.59 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | ESR1 | P03372 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | PDE4A | P27815 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5510390 | 1.00 | CES2 (0.62) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL76015 | 1.00 | CES2 (0.62) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL217920 | 1.00 | CES2 (0.62) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL216281 | 1.00 | CES2 (0.62) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL6755768 | 1.00 | CES2 (0.62) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL218312 | 1.00 | CES2 (0.62) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL78734 | 1.00 | CES2 (0.62) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL217644 | 1.00 | CES2 (0.62) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL218241 | 1.00 | CES2 (0.62) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL502175 | 1.00 | CES2 (0.62) | CES2CES1GPR84PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 764 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3538158-B1 | TREATMENT FOR FIBROSIS | GALMED RES AND DEVELOPMENT LTD (IL) | 2023-11-01 | — | — | EP | claimed |
| EP-3538159-B1 | INHIBITION OF FIBROSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE PATIENTS | GALMED RES AND DEVELOPMENT LTD (IL) | 2023-04-05 | — | — | EP | claimed |
| US-20220362263-A1 | TREATMENT FOR FIBROSIS AND INHIBITION OF FIBROSIS | GALMED RESEARCH AND DEVELOPMENT LTD (IL) | 2022-11-17 | — | — | US | claimed |
| US-11197870-B2 | Treatment for hepatic fibrosis | GALMED RESEARCH AND DEVELOPMENT LTD (IL) | 2021-12-14 | — | — | US | claimed |
| US-11166964-B2 | Treatment for modulating gut microbiota | GALMED RESEARCH AND DEVELOPMENT LTD (IL) | 2021-11-09 | — | — | US | claimed |
| CN-113166189-A | Gemcitabine amphiphilic prodrugs | 纳米医学控股有限公司 | 2021-07-23 | — | — | CN | claimed |
| US-20210169901-A1 | TREATMENT FOR MODULATING GUT MICROBIOTA | GALMED RESEARCH AND DEVELOPMENT LTD. (IL) | 2021-06-10 | — | — | US | claimed |
| EP-3538159-A1 | INHIBITION OF FIBROSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE PATIENTS | Galmed Research and Development Ltd. (IL) | 2019-09-18 | — | — | EP | claimed |
| EP-3538158-A1 | TREATMENT FOR FIBROSIS | Galmed Research and Development Ltd. (IL) | 2019-09-18 | — | — | EP | claimed |
| US-20190275061-A1 | INHIBITION OF FIBROSIS IN NON ALCOHOL FATTY LIVER DISEASE PATIENTS | GALMED RESEARCH AND DEVELOPMENT LTD (IL) | 2019-09-12 | — | — | US | claimed |
| WO-2018087600-A1 | INHIBITION OF FIBROSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE PATIENTS | GALMED RESEARCH AND DEVELOPMENT LTD. (IL) | 2018-05-17 | — | — | WO | claimed |
| US-20170196891-A1 | FATTY ACID BILE ACID CONJUGATES FOR TREATMENT OF LIPODYSTROPHY | GALMED RESEARCH AND DEVELOPMENT LTD. (IL) | 2017-07-13 | — | — | US | claimed |
| US-20120157419-A1 | METHODS AND COMPOSITIONS FOR TREATING ALZHEIMER'S DISEASE | GALMED INTERNATIONAL, LTD. (MT) | 2012-06-21 | — | — | US | claimed |
| WO-2011070140-A2 | LUBRICATING OIL COMPOSITION | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) | 2011-06-16 | — | — | WO | claimed |
| US-20090149537-A1 | Use of Bile Acid or Bile Salt Fatty Acid Conjugates | GALMED INTERNATIONAL LIMITED (MT) | 2009-06-11 | — | — | US | claimed |
| EP-1071702-A1 | FATTY ACID DERIVATIVES OF BILE ACIDS AND BILE ACID DERIVATIVES | Galmed International Ltd. (MT) | 2001-01-31 | — | — | EP | claimed |
| WO-1999052932-A1 | FATTY ACID DERIVATIVES OF BILE ACIDS AND BILE ACID DERIVATIVES | GALMED INTERNATIONAL LTD. (MT) | 1999-10-21 | — | — | WO | claimed |
| EP-0107850-B1 | AMINOGLYCOSIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-04-06 | — | — | EP | claimed |
| US-4493831-A | ANTIBIOTICS, VIRICIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-01-15 | — | — | US | claimed |
| EP-0107850-A1 | Aminoglycoside derivatives, processes for their preparation and pharmaceutical compositions containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-05-09 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157419-A1 | METHODS AND COMPOSITIONS FOR TREATING ALZHEIMER'S DISEASE | PSEN1, PSEN2, APP | CES2 506/4885CES1 76/4885GPR84 1825/4885 |
| US-20190275061-A1 | INHIBITION OF FIBROSIS IN NON ALCOHOL FATTY LIVER DISEASE PATIENTS | ACACA, LIPC, CYP46A1 | CES2 639/4885CES1 56/4885GPR84 801/4885 |
| US-20210169901-A1 | TREATMENT FOR MODULATING GUT MICROBIOTA | NR1H4, SLC10A2, FABP2 | CES2 1593/4885CES1 55/4885GPR84 372/4885 |
| US-11166964-B2 | Treatment for modulating gut microbiota | NR1H4, SLC10A2, FABP2 | CES2 1593/4885CES1 55/4885GPR84 372/4885 |
| US-20220362263-A1 | TREATMENT FOR FIBROSIS AND INHIBITION OF FIBROSIS | CYP46A1, LPCAT3, NR1H4 | CES2 1213/4885CES1 172/4885GPR84 581/4885 |
| US-11197870-B2 | Treatment for hepatic fibrosis | NR1H4, ACACA, LIPC | CES2 866/4885CES1 75/4885GPR84 748/4885 |
| US-20170196891-A1 | FATTY ACID BILE ACID CONJUGATES FOR TREATMENT OF LIPODYSTROPHY | CYP27A1, LIPC, SLC27A1 | CES2 202/4885CES1 29/4885GPR84 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.